Performance of Bioresorbable Polymer-Coated Everolimus-Eluting Synergy® Stent in Patients at High Bleeding Risk Undergoing Percutaneous Coronary Revascularization Followed by 1-Month Dual Antiplatelet Therapy

Trial Profile

Performance of Bioresorbable Polymer-Coated Everolimus-Eluting Synergy® Stent in Patients at High Bleeding Risk Undergoing Percutaneous Coronary Revascularization Followed by 1-Month Dual Antiplatelet Therapy

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 24 Aug 2017

At a glance

  • Drugs Everolimus (Primary) ; Aspirin
  • Indications Acute coronary syndromes; Angina pectoris; Coronary artery disease; Ischaemia
  • Focus Adverse reactions
  • Acronyms POEM
  • Most Recent Events

    • 17 Aug 2017 Status changed from not yet recruiting to recruiting.
    • 19 Apr 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top